Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOLLY L HAKE HARRIS

Allopathic & Osteopathic Physicians Dermatology

NPI
1538159207
CMS profile
890706
Location
SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$448.39

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $448.39 16

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Organogenesis Inc. $148.05 2
ABBVIE INC. $102.88 5
E.R. Squibb & Sons, L.L.C. $102.38 5
Lilly USA, LLC $42.25 2
Amgen Inc. $29.86 1
Fresenius Kabi USA, LLC $22.97 1

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOLLY L HAKE HARRIS

NPI 1538159207 · CMS profile ID 890706

Allopathic & Osteopathic Physicians / Dermatology

SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538159207?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538159207?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538159207?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1538159207?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $448.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $15.7112/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498277 CMS
Organogenesis Inc. $23.0511/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048149045 CMS
Fresenius Kabi USA, LLC $22.9711/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060095123 CMS
E.R. Squibb & Sons, L.L.C. $21.4509/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498237 CMS
ABBVIE INC. $28.8007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418761 CMS
ABBVIE INC. $26.4407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418759 CMS
E.R. Squibb & Sons, L.L.C. $21.7407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498201 CMS
Lilly USA, LLC $20.9205/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031478009 CMS
Organogenesis Inc. $125.0004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048149049 CMS
Amgen Inc. $29.8604/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020588395 CMS
Lilly USA, LLC $21.3303/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031576159 CMS
E.R. Squibb & Sons, L.L.C. $21.7403/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498105 CMS
ABBVIE INC. $16.0103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418757 CMS
ABBVIE INC. $15.8802/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418755 CMS
E.R. Squibb & Sons, L.L.C. $21.7401/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015498085 CMS
ABBVIE INC. $15.7501/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418753 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,931.99 7
PY2021 $29.68 2
PY2022 $77.19 4
PY2023 $448.39 16
PY2024 $189.69 8
PY2025 $60.71 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,042.82 1
PY2025 Principal investigator $214,389.75 98
PY2024 Recipient $6,347.66 1
PY2024 Principal investigator $293,318.73 162
PY2023 Principal investigator $348,782.35 197
PY2022 Recipient $100.00 2
PY2022 Principal investigator $164,469.18 81
PY2021 Principal investigator $449,676.56 73
PY2020 Recipient $15,456.30 2
PY2020 Principal investigator $642,662.67 80
PY2019 Recipient $418,491.34 8
PY2019 Principal investigator $1,194,399.32 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

197 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $141.70 12/22/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1045980645
Principal investigator 1 Acrotech Biopharma Inc. $8,124.12 12/20/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-302 No dispute reported 06/30/2026 1053741495
Principal investigator 1 Incyte Corporation $2,077.00 12/20/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916936
Principal investigator 1 Incyte Corporation $2,070.70 12/20/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916949
Principal investigator 1 Acrotech Biopharma Inc. $1,200.00 12/14/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-302 No dispute reported 06/30/2026 1053741437
Principal investigator 1 PFIZER INC. $1,544.40 12/08/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046175002
Principal investigator 1 Acrotech Biopharma Inc. $6,630.00 11/30/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-301 No dispute reported 06/30/2026 1053741349
Principal investigator 1 Incyte Corporation $410.00 11/20/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040916923
Principal investigator 1 Incyte Corporation $136.95 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916689
Principal investigator 1 Incyte Corporation $4,000.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916701
Principal investigator 1 Incyte Corporation $2,786.85 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916763
Principal investigator 1 Incyte Corporation $35.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916775
Principal investigator 1 Incyte Corporation $35.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916785
Principal investigator 1 Incyte Corporation $34.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916797
Principal investigator 1 Incyte Corporation $2,343.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916813
Principal investigator 1 Incyte Corporation $2,227.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916825
Principal investigator 1 Incyte Corporation $119.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916837
Principal investigator 1 Incyte Corporation $50.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916849
Principal investigator 1 Incyte Corporation $13,500.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916861
Principal investigator 1 Incyte Corporation $3,500.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916874
Principal investigator 1 Incyte Corporation $35.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916887
Principal investigator 1 Incyte Corporation $276.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916897
Principal investigator 1 Incyte Corporation $54.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916909
Principal investigator 1 Incyte Corporation $94.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916960
Principal investigator 1 Incyte Corporation $3,000.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917171
Principal investigator 1 Incyte Corporation $2,289.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917195
Principal investigator 1 Incyte Corporation $119.00 11/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917209
Principal investigator 1 PFIZER INC. $1,047.60 11/10/2023 Non-covered Recipient Entity
The South Bend Clinic Center for Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1046257537
Principal investigator 1 PFIZER INC. $403.92 11/10/2023 Non-covered Recipient Entity
The South Bend Clinic Center for Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1046258285
Principal investigator 1 Acrotech Biopharma Inc. $10,043.82 11/09/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-302 No dispute reported 06/30/2026 1053741295
Principal investigator 1 ABBVIE INC. $311.50 11/07/2023 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 998406027
Principal investigator 1 Incyte Corporation $31.98 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916985
Principal investigator 1 Incyte Corporation $23.74 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916998
Principal investigator 1 Incyte Corporation $63.96 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917011
Principal investigator 1 Incyte Corporation $33.54 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917023
Principal investigator 1 Incyte Corporation $50.31 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917035
Principal investigator 1 Incyte Corporation $67.08 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917045
Principal investigator 1 Incyte Corporation $47.48 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917061
Principal investigator 1 Incyte Corporation $159.90 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917073
Principal investigator 1 Incyte Corporation $5.94 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917085
Principal investigator 1 Incyte Corporation $13.86 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917097
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917131
Principal investigator 1 Incyte Corporation $19.52 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917145
Principal investigator 1 Incyte Corporation $34.16 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917159
Principal investigator 1 Incyte Corporation $63.96 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917221
Principal investigator 1 Incyte Corporation $67.08 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917229
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917243
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917256
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917269
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917281
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917293
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917305
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917317
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917329
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917341
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917355
Principal investigator 1 Incyte Corporation $9.76 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917367
Principal investigator 1 Incyte Corporation $19.52 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917379
Principal investigator 1 Incyte Corporation $19.52 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917393
Principal investigator 1 Incyte Corporation $19.52 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917403
Principal investigator 1 Incyte Corporation $19.52 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917415
Principal investigator 1 Incyte Corporation $19.52 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917429
Principal investigator 1 Incyte Corporation $19.52 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917441
Principal investigator 1 Incyte Corporation $19.52 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917453
Principal investigator 1 Incyte Corporation $34.16 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917467
Principal investigator 1 Incyte Corporation $34.16 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917479
Principal investigator 1 Incyte Corporation $34.16 11/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040917497
Principal investigator 1 Acrotech Biopharma Inc. $9,090.00 10/31/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-301 No dispute reported 06/30/2026 1053741257
Principal investigator 1 Incyte Corporation $2,755.15 10/23/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916727
Principal investigator 1 Incyte Corporation $2,042.00 10/23/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916741
Principal investigator 1 Incyte Corporation $2,255.00 10/23/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916751
Principal investigator 1 Incyte Corporation $3,300.00 10/23/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917182
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,044.90 10/13/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 1027489197
Principal investigator 1 Incyte Corporation $1,172.70 10/13/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040916713
Principal investigator 1 Incyte Corporation $22.29 10/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916973
Principal investigator 1 Incyte Corporation $120.02 10/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917107
Principal investigator 1 Incyte Corporation $24.30 10/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040917119
Principal investigator 1 Incyte Corporation $1,619.10 09/13/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915945
Principal investigator 1 Incyte Corporation $19,846.45 09/13/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915957
Principal investigator 1 Incyte Corporation $35.61 09/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916257
Principal investigator 1 Incyte Corporation $57.25 09/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916269
Principal investigator 1 Acrotech Biopharma Inc. $11,785.50 08/10/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-301 No dispute reported 06/30/2026 1053741031
Principal investigator 1 Acrotech Biopharma Inc. $6,726.24 08/10/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-302 No dispute reported 06/30/2026 1053741053
Principal investigator 1 PFIZER INC. $1,544.40 08/08/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046233521
Principal investigator 1 Eli Lilly and Company $62,926.44 08/01/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 3 DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1038126731
Principal investigator 1 Acrotech Biopharma Inc. $803.40 07/31/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-301 No dispute reported 06/30/2026 1053740999
Principal investigator 1 Incyte Corporation $5,318.10 07/19/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915969
Principal investigator 1 ABBVIE INC. $4,550.00 07/13/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998391503
Principal investigator 1 Incyte Corporation $47.48 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915981
Principal investigator 1 Incyte Corporation $59.35 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915993
Principal investigator 1 Incyte Corporation $67.08 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916007
Principal investigator 1 Incyte Corporation $33.54 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916019
Principal investigator 1 Incyte Corporation $63.96 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916031
Principal investigator 1 Incyte Corporation $50.31 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916043
Principal investigator 1 Incyte Corporation $35.61 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916057
Principal investigator 1 Incyte Corporation $427.82 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916069
Principal investigator 1 Incyte Corporation $30.42 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916081
Principal investigator 1 Incyte Corporation $109.95 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916095
Principal investigator 1 Incyte Corporation $304.06 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916109
Principal investigator 1 Incyte Corporation $3.24 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916121
Principal investigator 1 Incyte Corporation $42.25 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916133
Principal investigator 1 Incyte Corporation $43.28 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916147
Principal investigator 1 Incyte Corporation $6.10 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916161
Principal investigator 1 Incyte Corporation $6.80 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916173
Principal investigator 1 Incyte Corporation $22.29 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916185
Principal investigator 1 Incyte Corporation $22.20 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916197
Principal investigator 1 Incyte Corporation $127.08 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916209
Principal investigator 1 Incyte Corporation $22.90 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916221
Principal investigator 1 Incyte Corporation $24.34 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916233
Principal investigator 1 Incyte Corporation $76.84 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916245
Principal investigator 1 Incyte Corporation $33.54 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916283
Principal investigator 1 Incyte Corporation $63.96 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916295
Principal investigator 1 Incyte Corporation $59.35 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916307
Principal investigator 1 Incyte Corporation $59.35 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916319
Principal investigator 1 Incyte Corporation $67.08 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916331
Principal investigator 1 Incyte Corporation $47.48 07/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040916677
Principal investigator 1 PFIZER INC. $1,544.40 06/24/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046042239
Principal investigator 1 Incyte Corporation $2,466.00 06/14/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915795
Principal investigator 1 ABBVIE INC. $2,421.90 06/08/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998385859
Principal investigator 1 ABBVIE INC. $1,486.70 06/08/2023 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 998385861
Principal investigator 1 PFIZER INC. $1,815.00 06/03/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046327123
Principal investigator 1 Incyte Corporation $25.02 06/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915897
Principal investigator 1 Incyte Corporation $0.22 06/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915909
Principal investigator 1 ABBVIE INC. $1,000.00 05/24/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998384315
Principal investigator 1 ABBVIE INC. $120.00 05/24/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS) No dispute reported 06/30/2026 998384317
Principal investigator 1 ABBVIE INC. $119.00 05/23/2023 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 998384197
Principal investigator 1 Incyte Corporation $2,858.40 05/17/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915785
Principal investigator 1 Acrotech Biopharma Inc. $3,224.25 05/11/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-301 No dispute reported 06/30/2026 1053740781
Principal investigator 1 Incyte Corporation $61.26 05/02/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915883
Principal investigator 1 Incyte Corporation $29.90 04/22/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915613
Principal investigator 1 Incyte Corporation $60.00 04/22/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915625
Principal investigator 1 Incyte Corporation $60.00 04/22/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915637
Principal investigator 1 Incyte Corporation $26.25 04/22/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915675
Principal investigator 1 Incyte Corporation $30.00 04/22/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915701
Principal investigator 1 Incyte Corporation $5.08 04/22/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915713
Principal investigator 1 Incyte Corporation $29.90 04/21/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915563
Principal investigator 1 Incyte Corporation $60.00 04/21/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915579
Principal investigator 1 Incyte Corporation $60.00 04/21/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915589
Principal investigator 1 Incyte Corporation $139.56 04/21/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915601
Principal investigator 1 Incyte Corporation $627.76 04/21/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915649
Principal investigator 1 Incyte Corporation $29.90 04/21/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915725
Principal investigator 1 Incyte Corporation $710.38 04/20/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915527
Principal investigator 1 Incyte Corporation $94.61 04/20/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915539
Principal investigator 1 Incyte Corporation $139.56 04/20/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915551
Principal investigator 1 Incyte Corporation $35.00 04/20/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915661
Principal investigator 1 Incyte Corporation $5.02 04/20/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1040915687
Principal investigator 1 ABBVIE INC. $84.00 04/12/2023 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 998377699
Principal investigator 1 Incyte Corporation $3,250.80 04/12/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915773
Principal investigator 1 Incyte Corporation $1,200.00 04/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915737
Principal investigator 1 Incyte Corporation $180.00 04/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915749
Principal investigator 1 Incyte Corporation $976.00 04/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915761
Principal investigator 1 Incyte Corporation $2,400.00 04/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915921
Principal investigator 1 Incyte Corporation $1,200.00 04/05/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915933
Principal investigator 1 Incyte Corporation $48.78 04/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915809
Principal investigator 1 Incyte Corporation $25.02 04/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915821
Principal investigator 1 Incyte Corporation $20.42 04/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915833
Principal investigator 1 Incyte Corporation $2.16 04/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915847
Principal investigator 1 Incyte Corporation $50.36 04/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915859
Principal investigator 1 Incyte Corporation $0.66 04/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915871
Principal investigator 1 PFIZER INC. $1,544.40 03/25/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1045998091
Principal investigator 1 ABBVIE INC. $227.50 03/16/2023 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 998374273
Principal investigator 1 Incyte Corporation $4,587.30 03/15/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915255
Principal investigator 1 Amgen Inc. $27,000.00 02/24/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
P3 AD Monotherapy Induction No dispute reported 06/30/2026 1029655035
Principal investigator 1 PFIZER INC. $3,489.00 02/24/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1045932037
Principal investigator 1 Incyte Corporation $4,811.40 02/15/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915243
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,712.92 02/08/2023 Non-covered Recipient Entity
Qcare Site Services Inc
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1027489211
Principal investigator 1 Incyte Corporation $199.00 02/08/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915217
Principal investigator 1 Incyte Corporation $200.00 02/08/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915231
Principal investigator 1 Incyte Corporation $1,200.00 02/08/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915429
Principal investigator 1 Incyte Corporation $750.00 02/08/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915441
Principal investigator 1 Incyte Corporation $24.39 02/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915267
Principal investigator 1 Incyte Corporation $37.53 02/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915279
Principal investigator 1 Incyte Corporation $68.52 02/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915293
Principal investigator 1 Incyte Corporation $1.08 02/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915319
Principal investigator 1 Incyte Corporation $0.88 02/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915357
Principal investigator 1 Incyte Corporation $62.95 02/01/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915417
Principal investigator 1 Incyte Corporation $5,264.10 01/18/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915205
Principal investigator 1 ABBVIE INC. $1,521.80 01/12/2023 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 998366453
Principal investigator 1 Acrotech Biopharma Inc. $11,750.00 01/12/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-302 No dispute reported 06/30/2026 1053740033
Principal investigator 1 Acrotech Biopharma Inc. $11,773.18 01/12/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-301 No dispute reported 06/30/2026 1053740091
Principal investigator 1 Eli Lilly and Company $7,091.00 01/10/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1038126719
Principal investigator 1 Eli Lilly and Company $258.10 01/10/2023 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1038142055
Principal investigator 1 PFIZER INC. $1,722.50 01/07/2023 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1046356609
Principal investigator 1 Eli Lilly and Company $2,000.00 01/03/2023 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 1038149105
Principal investigator 1 Incyte Corporation $6.48 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915307
Principal investigator 1 Incyte Corporation $0.33 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915331
Principal investigator 1 Incyte Corporation $4.29 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915345
Principal investigator 1 Incyte Corporation $14.64 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915369
Principal investigator 1 Incyte Corporation $131.76 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915379
Principal investigator 1 Incyte Corporation $37.77 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915393
Principal investigator 1 Incyte Corporation $453.24 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915405
Principal investigator 1 Incyte Corporation $14.64 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915453
Principal investigator 1 Incyte Corporation $131.76 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915466
Principal investigator 1 Incyte Corporation $14.64 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915479
Principal investigator 1 Incyte Corporation $131.76 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915491
Principal investigator 1 Incyte Corporation $14.64 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915503
Principal investigator 1 Incyte Corporation $131.76 01/03/2023 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1040915515

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $109,356.47 1
PY2024 Amount invested $2,443.72 1
PY2024 Value of interest $109,356.47 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $106,912.75 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $154,320.92 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $88,340.48 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $80,642.76 1
PY2019 Amount invested $80,595.00 1
PY2019 Value of interest $806,985.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Digital Diagnostics Inc. $0.00 $109,356.47 Shares Owned by Immediate Family (Ben Clark) Immediate family member No dispute reported 06/30/2026 1254605365
PY2024 Digital Diagnostics Inc. $2,443.72 $109,356.47 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1153967797
PY2023 Digital Diagnostics Inc. $0.00 $106,912.75 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1060331987
PY2022 Digital Diagnostics Inc. $0.00 $154,320.92 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 961154523
PY2021 Digital Diagnostics Inc. $0.00 $88,340.48 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 855625849
PY2020 Digital Diagnostics Inc. $0.00 $80,642.76 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 737170185
PY2019 IDx Technologies Inc. $80,595.00 $806,985.00 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 676471935